Can serum angiogenin be used to improve the diagnostic performance in prostate cancer screening?

European Journal of Cancer Prevention

Volumn 23, Issue 3, 2014, Pages 166-172

  Pina, Francisco ^a,b   Botelho, Francisco ^a,b   Lopes, Tiago ^a,b   Lopes, Ivo ^a,b   Figueiredo, Gabriela ^a   Portugal, Raquel ^a   Ferro, Ana ^c   Cruz, Francisco ^a,b   Barros, Henrique ^b,c   Lunet, Nuno ^b  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Angiogenin; Diagnosis; Prostate cancer

Indexed keywords

ANGIOGENIN; BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; PANCREATIC RIBONUCLEASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; BIOPSY; BLOOD; EARLY DIAGNOSIS; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; EVALUATION STUDY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS;

AGED; BIOPSY; EARLY DETECTION OF CANCER; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RIBONUCLEASE, PANCREATIC; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84897452099     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3283647453     Document Type: Article

References (30)

1. Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G, Stauder R (2002). Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res 11:119-125.
2. Buchler P, Gazdhar A, Schubert M, Giese N, Reber HA, Hines OJ, et al. (2005). The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg 242:791-800, discussion-1.
3. Chen Y, Zhang S, Chen YP, Lin JY (2006). Increased expression of angiogenin in gastric carcinoma in correlation with tumor angiogenesis and proliferation. World J Gastroenterol 12:5135-5139.
4. Cleves MA, Rock L (2002). From the help desk: Comparing areas under receiver operating characteristic curves from two or more probit or logit models. Stata J 2:301-313.
5. Ellis LM, Fidler IJ (2001). Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, editors. The molecular basis of cancer. 2nd ed. Philadelphia: W. B. Saunders Company.
6. Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H, et al. (1998). Markers of tumor angiogenesis and proteolysis independently define high-And low-risk subsets of node-negative breast cancer patients. J Clin Oncol 16:3129-3136.
7. Etoh T, Shibuta K, Barnard GF, Kitano S, Mori M (2000). Angiogenin expression in human colorectal cancer: The role of focal macrophage infiltration. Clin Cancer Res 6:3545-3551.
8. Fang S, Repo H, Joensuu H, Orpana A, Salven P (2011). High serum angiogenin at diagnosis predicts for failure on long-Term treatment response and for poor overall survival in non-Hodgkin lymphoma. Eur J Cancer 47:1708-1716.
9. Gretzer MW, Partin AW (2007). Prostate cancer tumor markers. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 9th ed. Philadelphia: Library of Congress Cataloging-in-Publication Data.
10. Hartmann A, Kunz M, Kostlin S, Gillitzer R, Toksoy A, Brocker EB, et al. (1999). Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 59:1578-1583.
11. Hernandez DJ, Nielsen ME, Han M, Partin AW (2007). Contemporary evaluation of the D'amico risk classification of prostate cancer. Urology 70:931-935.
12. Hisai H, Kato J, Kobune M, Murakami T, Miyanishi K, Takahashi M, et al. (2003). Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. Clin Cancer Res 9:4852-4859.
13. Karaca B, Kucukzeybek Y, Gorumlu G, Erten C, Gul MK, Cengiz E, et al. (2008). Profiling of angiogenic cytokines produced by hormone-And drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol. Eur Cytokine Netw 19:176-184.
14. Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA, Cheng L (2005). Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res 11:8358-8363.
15. Kawada M, Inoue H, Arakawa M, Takamoto K, Masuda T, Ikeda D (2007). Highly tumorigenic human androgen receptor-positive prostate cancer cells overexpress angiogenin. Cancer Sci 98:350-356.
16. Khon EC, Liotta LA (2001). Metastasis and angiogenesis: Molecular dissection and novel applications. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, editors. The molecular basis of cancer. 2nd ed. Philadelphia: W. B. Saunders Company.
17. Manseck A, Froehner M, Oehlschlaeger S, Hakenberg O, Friedrich K, Theissig F, et al. (2000). Is systematic sextant biopsy suitable for the detection of clinically significant prostate cancer? Urol Int 65:80-83.
18. Marioni G, Marino F, Blandamura S, D'Alessandro E, Giacomelli L, Guzzardo V, et al. (2010). Neoangiogenesis in laryngeal carcinoma: Angiogenin and CD105 expression is related to carcinoma recurrence rate and disease-free survival. Histopathology 57:535-543.
19. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S (1999). Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer 86:316-324.
20. Passam FH, Sfiridaki A, Pappa C, Kyriakou D, Petreli E, Roussou PA, et al. (2008). Angiogenesis-related growth factors and cytokines in the serum of patients with B non-Hodgkin lymphoma; relation to clinical features and response to treatment. Int J Lab Hematol 30:17-25.
21. Schwartz B, Shoseyov O, Melnikova VO, McCarty M, Leslie M, Roiz L, et al. (2007). ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis. Cancer Res 67:5258-5266.
22. Shimoyama S, Gansauge F, Gansauge S, Negri G, Oohara T, Beger HG (1996). Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res 56:2703-2706.
23. Shimoyama S, Yamasaki K, Kawahara M, Kaminishi M (1999). Increased serum angiogenin concentration in colorectal cancer is correlated with cancer progression. Clin Cancer Res 5:1125-1130.
24. Verstovsek S, Kantarjian H, Aguayo A, Manshouri T, Freireich E, Keating M, et al. (2001). Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol 114:290-295.
25. Vickers AJ, Savage C, O'Brien MF, Lilja H (2009). Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27:398-403.
26. Vihinen P, Kallioinen M, Vuoristo MS, Ivaska J, Syrjanen KJ, Hahka-Kemppinen M, et al. (2007). Serum angiogenin levels predict treatment response in patients with stage IV melanoma. Clin Exp Metastasis 24:567-574.
27. Wittekind CF, Greene FL, RVP Hutter, Klimpfinger M, Sobin LH (2004). TNM Atlas. 5th ed. Heidelberg: Springer.
28. Yoshioka N,Wang L, Kishimoto K, Tsuji T, Hu GF (2006). A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA 103:14519-14524.
29. Yuan Y,Wang F, Liu XH, Gong DJ, Cheng HZ, Huang SD (2009). Angiogenin is involved in lung adenocarcinoma cell proliferation and angiogenesis. Lung Cancer 66:28-36.
30. Zhao H, Grossman HB, Delclos GL, Hwang LY, Troisi CL, Chamberlain RM, et al. (2005). Increased plasma levels of angiogenin and the risk of bladder carcinoma: From initiation to recurrence. Cancer 104:30-35.